Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Sep 10, 2014
Sangamo BioSciences Announces Target Date For First IND For Sangamo's In Vivo ZFN Genome-Editing Platform For Monogenic Diseases

Sep 8, 2014
Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV-Infected Subjects Treated with SB-728-T


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
11.74
Change:
- 0.63
Day High:
12.48
Day Low:
11.67
Volume:
1,210,800
4:00 PM ET on Sep 18, 2014

Shareholder Tools